UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $255.91 and traded as low as $238.54. UCB shares last traded at $238.54, with a volume of 17 shares changing hands.
Wall Street Analysts Forecast Growth
UCBJF has been the subject of several research analyst reports. Piper Sandler reiterated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.
Check Out Our Latest Research Report on UCBJF
UCB Stock Performance
About UCB
UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.
UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.
Featured Stories
- Five stocks we like better than UCB
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
- Liberty Energy’s AI Power Push Has Wall Street Divided
- Why Valley National Is Buying Growth Instead of Building It
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
